Promising Results of the Pfizer-BioNTech Vaccine Trial

Interim results are in from a large trial of an experimental COVID-19 vaccine. Drug maker Pfizer, working with German company BioNTech, says its vaccine appears to be working really well — it was found to be more than 90 percent effective. Today on Short Wave, host Maddie Sofia talks to NPR science correspondent Joe Palca about what that efficacy number means, details of the study and what more information about the vaccine researchers are awaiting.

Reach the show by emailing us at shortwave@npr.org.

See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.

NPR Privacy Policy